News Image

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

By Mill Chart

Last update: Jun 11, 2024

Here's BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) for you, a growth stock our stock screener believes is undervalued. NASDAQ:BMRN is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. Let's break it down further.


Affordable growth stocks image

Growth Examination for NASDAQ:BMRN

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:BMRN has received a 7 out of 10:

  • The Earnings Per Share has grown by an impressive 200.00% over the past year.
  • Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 13.74% in the last year.
  • The Revenue has been growing by 10.16% on average over the past years. This is quite good.
  • BMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.80% yearly.
  • BMRN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.74% yearly.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

A Closer Look at Valuation for NASDAQ:BMRN

ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:BMRN has earned a 6 for valuation:

  • Based on the Price/Earnings ratio, BMRN is valued cheaper than 94.11% of the companies in the same industry.
  • Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 93.59% of the companies are valued more expensively.
  • Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 94.11% of the companies are valued more expensively.
  • 95.15% of the companies in the same industry are more expensive than BMRN, based on the Price/Free Cash Flow ratio.
  • BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BMRN has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as BMRN's earnings are expected to grow with 61.90% in the coming years.

Exploring NASDAQ:BMRN's Health

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:BMRN has earned a 5 out of 10:

  • BMRN has an Altman-Z score of 5.92. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of BMRN (5.92) is better than 79.55% of its industry peers.
  • BMRN has a Debt to FCF ratio of 6.67. This is amongst the best in the industry. BMRN outperforms 94.80% of its industry peers.
  • A Debt/Equity ratio of 0.12 indicates that BMRN is not too dependend on debt financing.
  • A Current Ratio of 2.74 indicates that BMRN has no problem at all paying its short term obligations.

Understanding NASDAQ:BMRN's Profitability

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:BMRN, the assigned 7 is noteworthy for profitability:

  • BMRN has a better Return On Assets (2.99%) than 94.80% of its industry peers.
  • With an excellent Return On Equity value of 4.05%, BMRN belongs to the best of the industry, outperforming 95.15% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 2.42%, BMRN belongs to the top of the industry, outperforming 94.11% of the companies in the same industry.
  • Looking at the Profit Margin, with a value of 8.31%, BMRN belongs to the top of the industry, outperforming 95.49% of the companies in the same industry.
  • With an excellent Operating Margin value of 7.17%, BMRN belongs to the best of the industry, outperforming 94.45% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 79.23%, BMRN belongs to the top of the industry, outperforming 87.00% of the companies in the same industry.

More Affordable Growth stocks can be found in our Affordable Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of BMRN

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

BIOMARIN PHARMACEUTICAL INC

NASDAQ:BMRN (7/10/2024, 7:00:01 PM)

After market: 82.29 0 (0%)

82.29

-0.69 (-0.83%)

Follow us for more